Investigating the impact of regular cardio selective beta blockers on recovery with beta agonists following methacholine bronchoconstriction challenge in Asthmatics

Waikato District Health Board, Respiratory Research Fund0 个研究点目标入组 21 人开始时间: 2018年3月1日最近更新: 2020年2月3日

适应症

试验速览

暂无简介。

•Physician diagnosis of asthma
•Airway hyper responsiveness. Demonstrated with post mannitol ( a 15 percent decrease in FEV1 at a cumulative mannitol dose PD15 <635mg/ml)
•Over 18 years of age

•Pre spirometry FEV1 < 60% predicted or < 1.5L
•Dyspnoea at rest
•Past history of hypotension (baseline BP <100/60)
•ECG abnormalities that could interfere with the interpretation of the study:
•HR<60/min
•Symptomatic hypotension
•ECG findings of severe 1st degree, or 2nd & 3rd degree heart block (defined as PR interval > 0.28s)
•LBBB & RBBB are NOT excluded.
•Known adverse reaction to beta blockers or mannitol
•On other drugs that commonly interact with beta blockers (amiodarone, verapramil, cimetidine, digoxin, phenytoin)
•Already taking beta blockers – including eye-drops.
•Smoking history of >10 pack years
•Recent exacerbation as defined by oral corticosteroid use/hospitalisation within 6 weeks of recruitment
•Pregnant (negative pregnancy test required)
•Under 18 year of age
•Unsuitability as defined by the study doctor

发起方

Waikato District Health Board, Respiratory Research Fund